bioRxiv Science⌕ Search

Biology subjects

McConkey, D.

Publications and source records attributed to McConkey, D..

3 recordsLinked to original sources

Heterogeneous Effects of Src Inhibition on Determinants of Metastasis in Preclinical Models of Human Bladder Cancer

BackgroundPast work in preclinical models of solid tumors have implicated SRC in invasion and metastasis, but also demonstrated it inhibited bladder cancer metastasis. ObjectiveDetermine if the role of SRC in metastasis is dependent on bladder cancer molecular subtype membership. MethodsWe analyzed large public datasets, performed in vitro invasion and migration assays using small-molecule and doxycycline inducible SRC knock-down constructs, and in vivo experimental metastasis assays. ResultsLooking at large public datasets, we found SRC is upregulated in luminal papillary muscle invasive bladder cancer. Using the consensus classifier on RNA expression from 30 cell lines, we demonstrated that chemical SRC antagonists inhibited migration in luminal papillary cells but had little effect in basal/squamous lines. Conditional SRC knockdown inhibited migration in luminal papillary RT112 cells, whereas it increased migration and reduced proliferation in luminal papillary UM-UC6 cells. Regardless, these effects did not affect levels or sites of experimental metastasis in vivo. ConclusionsThe results support the conclusion that SRCs biological effects in bladder cancer are not primarily involved in promoting invasion and metastasis. Further work is required to define SRCs roles in luminal papillary bladder cancers.

cancer biology↗

Improved bladder cancer antitumor efficacy with a recombinant BCG that releases a STING agonist

Despite the introduction of several new agents for the treatment of bladder cancer (BC), intravesical BCG remains a first line agent for the management of non-muscle invasive bladder cancer. In this study we evaluated the antitumor efficacy in animal models of BC of a recombinant BCG known as BCG-disA-OE that releases the small molecule STING agonist c-di-AMP. We found that compared to wild-type BCG (BCG-WT), in both the orthotopic, carcinogen-induced rat MNU model and the heterotopic syngeneic mouse MB-49 model BCG-disA-OE afforded improved antitumor efficacy. A mouse safety evaluation further revealed that BCG-disA-OE proliferated to lesser degree than BCG-WT in BALB/c mice and displayed reduced lethality in SCID mice. To probe the mechanisms that may underlie these effects, we found that BCG-disA-OE was more potent than BCG-WT in eliciting IFN-{beta} release by exposed macrophages, in reprogramming myeloid cell subsets towards an M1-like proinflammatory phenotypes, inducing epigenetic activation marks in proinflammatory cytokine promoters, and in shifting monocyte metabolomic profiles towards glycolysis. Many of the parameters elevated in cells exposed to BCG-disA-OE are associated with BCG-mediated trained innate immunity suggesting that STING agonist overexpression may enhance trained immunity. These results indicate that modifying BCG to release high levels of proinflammatory PAMP molecules such as the STING agonist c-di-AMP can enhance antitumor efficacy in bladder cancer.

cancer biology↗